Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

By Kane John M.  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 917-925

Informa Healthcare

Access to resources Recommend Favorite

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia*

By Edwards Natalie C.   Pesa Jacqueline   Meletiche Dennis M.   Engelhart Luella   Thompson Ann K.   Sherr Jay   Dirani Riad  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3341-3355

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia

By Ascher-Svanum Haya   Stensland Michael D.   Peng Xiaomei   Faries Douglas E.   Stauffer Virginia L.   Osuntokun Olawale O.   Kane John M.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 115-122

Informa Healthcare

Access to resources Recommend Favorite

Atypical antipsychotics for older adults: are they safe and effective as we once thought?

By Jeste Dilip V   Maglione Jeanne E  

Journal of Comparative Effectiveness Research, Vol. 2, Iss. 4, 2013-07 ,pp. : 355-358

Future Medicine

Access to resources Recommend Favorite

Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study

By Andrezina R.   Marcus R. N.   Oren D. A.   Manos G.   Stock E.   Carson W. H.   McQuade R. D.  

Current Medical Research and Opinion, Vol. 22, Iss. 11, 2006-11 ,pp. : 2209-2219

Informa Healthcare

Access to resources Recommend Favorite